EVAXION_DEEPBLUE_RGB.png
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
12 nov. 2024 08h00 HE | Evaxion Biotech
New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the successful design of a proprietary...